Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 4, pp. 411-411
Open Access | Times Cited: 278

Showing 1-25 of 278 citing articles:

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Thomas Bieber
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 1, pp. 21-40
Open Access | Times Cited: 412
Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
Gabsik Yang, Jin Kyung Seok, Han Chang Kang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2867-2867
Open Access | Times Cited: 302
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1409-1431
Open Access | Times Cited: 239
New treatments in atopic dermatitis
Neha Puar, Raj Chovatiya, Amy S. Paller
Annals of Allergy Asthma & Immunology (2020) Vol. 126, Iss. 1, pp. 21-31
Closed Access | Times Cited: 165
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Jonathan I. Silverberg, Emma Guttman‐Yassky, Diamant Thaçi, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 12, pp. 1080-1091
Closed Access | Times Cited: 138
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Pavel Kolkhir, Daniel Elieh Ali Komi, Martin Metz, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 5, pp. 294-308
Closed Access | Times Cited: 125
Systemic Immunomodulatory Treatments for Atopic Dermatitis
Aaron M. Drucker, Deanna E. Morra, David Prieto‐Merino, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 5, pp. 523-523
Open Access | Times Cited: 114
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Thanaporn Ratchataswan, Tina Banzon, Jacob P. Thyssen, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 3, pp. 1053-1065
Open Access | Times Cited: 105
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis
Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 2, pp. 182-182
Open Access | Times Cited: 65
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 6, pp. 740-748
Open Access | Times Cited: 59
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Alexandro Chu, Melanie Wong, Daniel Rayner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1470-1492
Open Access | Times Cited: 54
Expert consensus on the systemic treatment of atopic dermatitis in special populations
David N. Adam, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 6, pp. 1135-1148
Open Access | Times Cited: 47
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
Stephan Weidinger, Thomas Bieber, Michael J. Cork, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 5, pp. 531-539
Open Access | Times Cited: 45
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 45
Sensory neurons promote immune homeostasis in the lung
Masato Tamari, Kate L. Del Bel, Aaron Ver Heul, et al.
Cell (2023) Vol. 187, Iss. 1, pp. 44-61.e17
Open Access | Times Cited: 42
Recent Advancements in the Atopic Dermatitis Mechanism
Maria Savva, Nikolaos G. Papadopoulos, Stamatios Gregoriou, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 2
Open Access | Times Cited: 17
New and Emerging Systemic Treatments for Atopic Dermatitis
Megan Newsom, Arjun M. Bashyam, Esther A. Balogh, et al.
Drugs (2020) Vol. 80, Iss. 11, pp. 1041-1052
Open Access | Times Cited: 120
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
Jonathan I. Silverberg, Jacob P. Thyssen, Kyle Fahrbach, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 9, pp. 1797-1810
Open Access | Times Cited: 98
Itch: A Paradigm of Neuroimmune Crosstalk
Fang Wang, Brian Kim
Immunity (2020) Vol. 52, Iss. 5, pp. 753-766
Open Access | Times Cited: 97
Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis
Jianghui Meng, Yanqing Li, Michael J. M. Fischer, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 71
The use of biologics in food allergy
Alessandro Fiocchi, Brian P. Vickery, Robert A. Wood
Clinical & Experimental Allergy (2021) Vol. 51, Iss. 8, pp. 1006-1018
Closed Access | Times Cited: 70
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Hidaya A. Kader, Muhammad Azeem, Suhib A. Jwayed, et al.
Cells (2021) Vol. 10, Iss. 6, pp. 1392-1392
Open Access | Times Cited: 63
Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
Andreas Wollenberg, Lisa A. Beck, Marjolein de Bruin‐Weller, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 3, pp. 453-465
Open Access | Times Cited: 63
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
Celina Dubin, Ester Del Duca, Emma Guttman‐Yassky
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 8, pp. 835-852
Closed Access | Times Cited: 59
Page 1 - Next Page

Scroll to top